Table 1.
Demographic and clinical characteristics of patients.
| Characteristics | All patients (N = 33) |
NRICM101 (n = 12) |
Non-NRICM101 (n = 21) |
|---|---|---|---|
| Median age, years (range) | 40 (18−80) | 57 (29−80) | 33 (18−74) |
| Age group, years (%) | |||
| < 30 | 10 (30.3 %) | 1 (8.3 %) | 9 (42.9 %) |
| 30−39 | 6 (18.2 %) | 2 (16.7 %) | 4 (19.0 %) |
| 40−49 | 3 (9.1 %) | 1 (8.3 %) | 2 (9.5 %) |
| 50−59 | 6 (18.2 %) | 2 (16.7 %) | 4 (19.0 %) |
| 60−80 | 8 (24.2 %) | 6 (50.0 %) | 2 (9.5 %) |
| Sex (%) | |||
| Male | 15 (45.5 %) | 6 (50.0 %) | 9 (42.9 %) |
| Female | 18 (54.5 %) | 6 (50.0 %) | 12 (57.1 %) |
| Severity1 (%) | |||
| Mild | 29 (87.9 %) | 8 (66.7 %) | 21 (100.0 %) |
| Severe2 | 3 (9.1 %) | 3 (25.0 %) | – |
| Critical2 | 1 (3.0 %) | 1 (8.3 %) | – |
| Median days from hospitalization to 3 N3 (range) | 26 (8−51) | 33.5 (8−44) | 22 (9−51) |
| Median days from hospitalization to intervention (range) | – | 21.5 (0−33) | – |
| Median days from intervention to 3 N (range) | – | 9 (4−18) | – |
| Coexisting conditions (Comorbidity, %) | 11 (33.3 %) | 8 (66.7 %) | 3 (14.3 %) |
| Hypertension | 4 (12.1 %) | 4 (33.3 %) | – |
| Hyperlipidemia | 4 (12.1 %) | 3 (25.0 %) | 1 (4.8 %) |
| Type 2 diabetes | 3 (9.1 %) | 3 (25.0 %) | – |
| Others | 7 (21.2 %) | 4 (33.3 %) | 3 (14.3 %) |
| Adverse effects reported | – | 0 | – |
1
:Disease severity was defined according to the "Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)" proposed by the United States Centers for Disease Control and Prevention.
2
:Severe and critical cases presenting cardiovascular symptoms were given additional TCM, in addition to NRICM101.
3
:3 N denotes patient respiratory specimens testing negative for SARS-CoV-2 three times in a row, with specimens collected ≧24 h apart.